South Africa asks SII to take back 1 mn Covid vaccines

A phase I/II trial conducted by University of Witwatersrand and Oxford
University on 2,000 volunteers with a median age of 31 years found
that though the vaccine prevented severe disease and death in the
volunteers, its efficacy against mild and moderate Covid-19 cases was
21.9%, well below the 50% threshold required for vaccine approval.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/south-africa-asks-sii-to-take-back-1-m-covid-vaccines/articleshow/80947580.cms

Comments

Popular posts from this blog

Pharma Production Executive Post Vacancy @ Intas

Pharos of Chaos

HILR Intersession: Mollie Crawford-Volk: Velazquez' "Las Meninas" and its Modern Progeny